Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

More documents

Recommendations

Info

APPENDIX 12. Preclinical Studies Service Organizations (cont’d) Regulatory Qualifica- Types of Clients Company/ URL Contact Information Therapeutic Expertise and Types of Services Structure Number and Type of tions Staffing CDRD operates to: GLP Centre for Drug Research and Development (CDRD) www.cdrd.ca 308 CDRD employs 75 staff located in Vancouver CDRD is a grantfundedorganisation providing for-profit services and tools used in Pharma and Biomedical development. Located at UBC in Vancouver CDRD and DDI Suite 364 2259 Lower Mall, Vancouver, B.C., V6T 1Z4 Tel: 604-221-7750 Fax: 604-221-7753 info@cdrd.ca Director CDRD: Pieter Cullis pcullis@crdr.ca CEO: Natalie Dakers ndakers@crdr.ca Project Development: John Coleman jcoleman@cdrd.ca Tel : 604-221-7750 x 117 Business Development: Kamran Alam kalam@crdr.ca Tel : 604-221-7750 x 125 - Drug Development, Inc. Director Operations: Mike Parr Tel : 604-221-7750 x 176 ddi@cdrd.ca BRITISH COLUMBIA CDRD provides services to predominantly 287 members of the B.C. science community (research institutions and companies) with other clients in Canada and North America. CDRD is broadening activities beyond B.C. into other areas of Canada and North America. CDRD provides drug development expertise and infrastructure to enable researchers throughout B.C. to develop promising drug candidates. It has a goal to simultaneously improve efficacy, ADME, and toxicology results. The CDRD commercial arm, Drug Development Inc (DDI), licenses technologies from affiliated institutions CDRD Capabilities include: • Target Validation Genomic and proteomic techniques, including microarray analyses of gene expression, comparative proteomic analyses, and bioinformatics. This technology applies to areas as diverse as identifying novel drug targets and determining side effects. • Drug Screening Drug Screening Division offers in-vitro and cell-based assays suitable for medium- to high-throughput drug screening with liquid-handling robots and a suite of instruments for the detection of biological or biochemical activity. • Libraries of defined pure chemicals from discovery and combinatorial chemistry, together with peptides and natural product extracts, are available for screening for potential drug activity. • Medicinal Chemistry Medicinal Chemistry Division optimizes lead compounds derived from rational design and screening processes; with modern synthetic methods and principles to design and synthesize novel compounds for biological and toxicological evaluation. • Drug Delivery Drug Delivery division focuses drug formulation, both NCEs and novel macromolecular therapeutics from proteomics and genomics research. CDRD has capabilities in all types of drug formulation, and specific expertise in nano-delivery. Nano-particulate carriers can target drugs specifically to disease sites • Pharmacology and Toxicology Pharmacology and Toxicology Division provides in-vitro and in-vivo assays to determine the safety and efficacy of novel therapies. Drug-like qualities can be evaluated in vitro using a broad range of assays that measure efficacy, drug-drug interactions, cardiovascular safety, absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox).
Regulatory Qualifica- Types of Clients Company/ URL Contact Information Therapeutic Expertise and Types of Services Structure Number and Type of tions Staffing Certified to Quality standards: 19 persons located in BCIT Product and Process Applied Research Team (PART) Technology Centre www.bcit.ca/appliedresearch/ part/ CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP ISO 9001 for non medical products ISO 13485 for medical devices Predominantly providing development services to B.C., including: • Starguide Technologies Inc. • UBC University Industry Liaison Office • UBC Department of Mechanical • Engineering • Hollister Incorporated • WorkSafe B.C. • B.C. Women’s and Children’s Hospital Applied research services provided through the BCIT (B.C. Institute of Technology) PART is a specialist medical device consultancy. It provides applied research services to validate and commercialize medical, industrial and consumer products and processes, and perform contract services to research and develop proof of concept prototypes. It consists of a team of business analysts, social scientists, engineers, technologists, industrial designers, manufacturing specialists and project managers able to conduct and co-ordinate all aspects of verification and validation of a specific product’s performance. PART offers a systems based approach to strategic innovation for products and processes that exceed their expectations. Product areas include consumer and industrial electro/mechanical/textile including Medical, Safety and Assistive Devices product research & development. BCIT Technology Centre 4355 Mathissi Place Burnaby B.C. V5G 4S8 Tel: 604-432-8761 Fax: 778-329-0314 Contacts : Director of BCIT Health Technology Research Group: Nancy Paris Nancy_Paris@bcit.ca Joe Newton, Program Head joe_newton@bcit.ca 309
Page 1:
1 33 0 34 0 M A G N E T I C V A R 9
Page 4 and 5:
ii BRITISH COLUMBIA
Page 6 and 7:
2 EXECUTIVE SUMMARY BRITISH COLUMBI
Page 8 and 9:
4 INTRODUCTION BRITISH COLUMBIA Wit
Page 10 and 11:
6 Health Authority (URL) Key Facili
Page 12 and 13:
8 FIGURE 2. Clinical Trials Units,
Page 14 and 15:
10 Facility (URL if available) Pedi
Page 16 and 17:
12 Facility (URL if available) Mood
Page 18 and 19:
14 Facility (URL if available) Down
Page 20 and 21:
16 Facility (URL if available) Clin
Page 22 and 23:
18 Facility (URL if available) Gast
Page 24 and 25:
20 TABLE 3. Clinical Trials Support
Page 26 and 27:
22 Much clinical research - particu
Page 28 and 29:
24 FIGURE 3. Source of Funds for Cl
Page 30 and 31:
26 BRITISH COLUMBIA FIGURE 7. Thera
Page 32 and 33:
28 BRITISH COLUMBIA Clinical Invest
Page 34 and 35:
Disease Area Population Information
Page 36 and 37:
32 CV/Cardiology CNS Pulmonary Canc
Page 38 and 39:
34 TABLE 9. Health Economics and He
Page 40 and 41:
36 TABLE 10. Epidemiology and Surve
Page 42 and 43:
38 TABLE 12. Provincial Networks Th
Page 44 and 45:
40 Network B.C. Investigator’s Ro
Page 46 and 47:
42 Network B.C. Investigator’s Ro
Page 48 and 49:
44 TABLE 14. Independent Clinical T
Page 50 and 51:
46 COMPARATIVE POSITIONING OF B.C.
Page 52 and 53:
48 ACKNOWLEDGEMENTS BRITISH COLUMBI
Page 54 and 55:
50 APPENDIX 1-2 TABLE OF CONTENTS B
Page 56 and 57:
52 PROVINCIAL HEALTH SERVICES AUTHO
Page 58 and 59:
54 BRITISH COLUMBIA Edward Miller C
Page 60 and 61:
56 BRITISH COLUMBIA Radiation Thera
Page 62 and 63:
58 The Unit has 15 Principal Invest
Page 64 and 65:
60 BRITISH COLUMBIA Neonatal Resear
Page 66 and 67:
62 The B.C. Children’s Hospital p
Page 68 and 69:
64 BRITISH COLUMBIA The clinical tr
Page 70 and 71:
66 FRASER HEALTH AUTHORITY BRITISH
Page 72 and 73:
68 BRITISH COLUMBIA tional therapis
Page 74 and 75:
70 PROVIDENCE HEALTH CARE SOCIETY 4
Page 76 and 77:
72 BRITISH COLUMBIA Quality control
Page 78 and 79:
74 Clinical trials investigators in
Page 80 and 81:
76 The facility has 13 investigator
Page 82 and 83:
78 Staffing of the Centre is as fol
Page 84 and 85:
80 Investigators: • Ayas, Najib
Page 86 and 87:
82 BRITISH COLUMBIA Quality control
Page 88 and 89:
84 The Research Group consists of t
Page 90 and 91:
86 BRITISH COLUMBIA Multiple Sclero
Page 92 and 93:
88 BRITISH COLUMBIA Gastroenterolog
Page 94 and 95:
Since the Centre is located in St.
Page 96 and 97:
TABLE A1. Providence Health Care So
Page 98 and 99:
94 BRITISH COLUMBIA FIGURE A9. Cent
Page 100 and 101:
96 BRITISH COLUMBIA The Unit suppor
Page 102 and 103:
TABLE A2. CFRI Program-affiliated R
Page 104 and 105:
100 BRITISH COLUMBIA Quality contro
Page 106 and 107:
102 BRITISH COLUMBIA • Knowledge
Page 108 and 109:
104 Its staffing is as follows: Stu
Page 110 and 111:
106 APPENDIX 3. QUALITY CONTROL/ QU
Page 112 and 113:
APPENDIX 5. CLINICAL TRIALS TRAININ
Page 114 and 115:
APPENDIX 5. Clinical Trials Trainin
Page 116 and 117:
112 APPENDIX 6 TABLE OF CONTENTS BR
Page 118 and 119:
6.1 Clinical Trials Researchers Lis
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Pediatrics INSTITUTION EMAIL URL DI
Page 244 and 245:
Pediatrics (cont’d) INSTITUTION E
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
248 APPENDICES 7-13 TABLE OF CONTEN
Page 254 and 255:
250 TABLE A3. Patient and Addiction
Page 256 and 257:
252 TABLE A3. Patient and Addiction
Page 258 and 259:
APPENDIX 8. PROVINCIAL AND NATIONAL
Page 260 and 261:
APPENDIX 8. Provincial And National
Page 262 and 263: 258 APPENDIX 9. Healthcare Research
Page 264 and 265: APPENDIX 9. Healthcare Research Cen
Page 288 and 289: APPENDIX 10. NATIONAL AND INTERNATI
Page 290 and 291: Networks In Which B.C.’s Clinical
Page 296 and 297: APPENDIX 11. INDEPENDENT CLINICAL T
Page 298 and 299: APPENDIX 11. Independent Clinical T
Page 310 and 311: APPENDIX 12. PRECLINICAL STUDIES SE
Page 314 and 315: APPENDIX 12. Preclinical Studies Se
Page 316 and 317: 312 B.C. Centre for Disease Control
Page 318 and 319: 314 University of Victoria Brenda D
Page 320: 316 BRITISH COLUMBIA
show all

Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

Create successful ePaper yourself

Delete template?

Save as template?